Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$2.03M+334.46%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brian Carrico
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 24
- Beta
- 1.38
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -8.62
Financials
Revenue
$2.03M+334.5%Net Income
$-6.55MEBITDA
$-6.51MFree Cash Flow
$-2.27MEPS (diluted)
$-0.52Shares Outstanding (diluted)
12.99M+141.2%Operating Expenses
$8.34MCash & Debt
$4.48MReturn of Capital
$18.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.57M | $-7.80M | $-0.95 |
| 2024 | $2.69M | $-8.24M | $-1.22 |
| 2023 | $2.46M | $-14.63M | $-2.32 |
| 2022 | $2.68M | $-4.78M | $-0.57 |
| 2021 | $2.72M | $-3.03M | $-0.62 |
| 2020 | $1.93M | $-3.73M | $-0.80 |
Valuation
NRXShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
160-7.25%Social Signal Score
Mentions (11)
- Newsseekingalpha.com·13d ago·Positive
NeurAxis, Inc. (NRXS) Q3 2026 Earnings Call Transcript NeurAxis, Inc. (NRXS) Q3 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·13d ago·Neutral
NeurAxis Reports Record Third Quarter 2026 Financial Results Driven by 150% Year Over Year Revenue Growth CARMEL, Ind., Nov. 09, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the third quarter period ended September 30, 2026.
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
NeurAxis to Host Third Quarter 2026 Results and Business Update Call on Monday, November 9, 2026 CARMEL, Ind., Oct. 27, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its third quarter period ended September 30, 2026, on Monday, November 9, 2026, before market open.
View source ↗ - Newsglobenewswire.com·38d ago·Negative
NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives Total national coverage footprint for PENFS increases to over 147 million covered lives Total national coverage footprint for PENFS increases to over 147 million covered lives
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer CARMEL, Ind., Sept. 29, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced the appointment of Craig Blanchard as Chief Commercial Officer.
View source ↗ - Newsglobenewswire.com·67d ago·Negative
…ding Access to Over 18 million additional Covered Lives CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced significant new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation (“PENFS”).
View source ↗ - Newsglobenewswire.com·67d ago·Neutral
…e in the Lytham Partners Fall 2026 Investor Conference CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.
View source ↗ - Newszacks.com·68d ago·Positive
Neuraxis Gains Nearly 137% in a Year: What's Driving the Stock? NRXS is benefiting from stronger IB-Stim volumes, broader reimbursement and VA access, but incomplete payer coverage and cash needs remain challenges.
View source ↗ - Newsseekingalpha.com·68d ago·Positive
NeurAxis, Inc. (NRXS) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript NeurAxis, Inc. (NRXS) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript
View source ↗ - Newszacks.com·100d ago·Positive
NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up NeurAxis delivers record second-quarter 2026 revenues as stronger IB-Stim demand, higher pricing and an improved reimbursement mix lift gross margin.
View source ↗ - Newsseekingalpha.com·103d ago·Positive
NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript
View source ↗
Earnings
Thu, Mar 18(in 4 months)
Consensus estimate $-0.21 per share
Typical surprise -15.8% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 9$-0.52 vs $-0.21miss
- Tue, Aug 11$-0.19 vs $-0.32beat
- Tue, May 12$-0.18 vs $-0.19beat
- Thu, Mar 19$-0.17 vs $-0.21beat
- Mon, Nov 10$-0.24 vs $-0.20miss
- Tue, Aug 12$-0.22 vs $-0.19miss
Estimates and results for NRXS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NRXS officers and directors.
- Bought
- $2.3m
- Sold
- $652k
11 trades
2 trades
- Carrico Brian Allenbought
- Carrico Thomas Joesephbought
- Henrichs Timothy Robertbought
- Henrichs Timothy Robertbought
- Carrico Thomas Joesephbought
- Carrico Brian Allenbought
- Hannasch Brianbought
- Hannasch Brianbought
87 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NRXS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
